Olema Pharmaceuticals OLMA Stock
Olema Pharmaceuticals Price Chart
Olema Pharmaceuticals OLMA Financial and Trading Overview
| Olema Pharmaceuticals stock price | 10.86 USD |
| Previous Close | 8.93 USD |
| Open | 8.93 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 3100 |
| Day's Range | 8.69 - 9.36 USD |
| 52 Week Range | 2.19 - 9.87 USD |
| Volume | 569.15K USD |
| Avg. Volume | 235.47K USD |
| Market Cap | 370.12M USD |
| Beta (5Y Monthly) | 2.329406 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.67 USD |
OLMA Valuation Measures
| Enterprise Value | 178.03M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0266666 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.0984516 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.576 |
Trading Information
Olema Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.329406 |
| 52-Week Change | 151.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.87 USD |
| 52 Week Low | 2.19 USD |
| 50-Day Moving Average | 5.64 USD |
| 200-Day Moving Average | 4.03 USD |
OLMA Share Statistics
| Avg. Volume (3 month) | 235.47K USD |
| Avg. Daily Volume (10-Days) | 399.53K USD |
| Shares Outstanding | 40.76M |
| Float | 20.59M |
| Short Ratio | 4.95 |
| % Held by Insiders | 6.86% |
| % Held by Institutions | 89.10% |
| Shares Short | 1.03M |
| Short % of Float | 3.85% |
| Short % of Shares Outstanding | 2.52% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.94% |
| Return on Equity (ttm) | -50.012% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -112963000 USD |
| Net Income Avi to Common (ttm) | -110043000 USD |
| Diluted EPS (ttm) | -2.8 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 185.95M USD |
| Total Cash Per Share (mrq) | 4.59 USD |
| Total Debt (mrq) | 2.29M USD |
| Total Debt/Equity (mrq) | 1.31 USD |
| Current Ratio (mrq) | 9.758 |
| Book Value Per Share (mrq) | 4.327 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -84553000 USD |
| Levered Free Cash Flow (ttm) | -44182000 USD |
Profile of Olema Pharmaceuticals
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 512 2nd Street |
| ZIP | 94107 |
| Phone | (650) 243-5555 |
| Website | https://olema.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 62 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Q&A For Olema Pharmaceuticals Stock
What is a current OLMA stock price?
Olema Pharmaceuticals OLMA stock price today per share is 10.86 USD.
How to purchase Olema Pharmaceuticals stock?
You can buy OLMA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Olema Pharmaceuticals?
The stock symbol or ticker of Olema Pharmaceuticals is OLMA.
Which industry does the Olema Pharmaceuticals company belong to?
The Olema Pharmaceuticals industry is Biotechnology.
How many shares does Olema Pharmaceuticals have in circulation?
The max supply of Olema Pharmaceuticals shares is 55.91M.
What is Olema Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Olema Pharmaceuticals PE Ratio is now.
What was Olema Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Olema Pharmaceuticals EPS is -2.14 USD over the trailing 12 months.
Which sector does the Olema Pharmaceuticals company belong to?
The Olema Pharmaceuticals sector is Healthcare.
Olema Pharmaceuticals OLMA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}